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cine and ultrasound has led to the possibility of in utero diagnosis
and treatment with intrauterine transfusions. Rare cases of prema-
ture infants surviving and undergoing chronic transfusion therapy
have been reported. Hematopoietic stem cell transplant (HSCT)
has become increasingly used to cure beta thalassemia, and pro-
vides the potential to cure 0thalassemia. To date, 3 reported cases
of 0thalassemia have been treated with HSCT. Two children
underwent matched sibling HSCT at 20 and 21 months of age and
one a 5/6 HLA matched sibling umbilical cord blood transplant
(UCBT). One child had received intrauterine transfusions. We
report a case of an infant with 0thalassemia successfully treated
with intrauterine transfusions followed by unrelated donor UCBT.
The mother, of Cambodian descent, noticed decreased fetal move-
ment at 23 weeks gestation and ultrasound revealed hydrops fetalis.
Based on nationality and previous fetal loss, the suspicion of
0thalassemia was raised. UCB sampling revealed a hypochromic,
microcytic anemia with target cells. The Hgb electrophoresis dem-
onstrated Hgb Barts and Portland. Subsequent genotyping con-
ﬁrmed deletion of all 4 -globin genes. The patient received 3
intrauterine transfusions prior to delivery at 32 weeks. The hospital
course was relatively uneventful and included PRBC transfusions.
After discharge, he received 3 transfusions. Following informed
consent, at 6 months of age, he was conditioned for transplant with
busulfan, cytoan and ATG. Lacking an HLA matched sibling, he
received a 5/6 HLA matched unrelated donor UCB unit delivering
11.8  107 nucleated cells/kg. Neutrophil engraftment
(ANC500) was achieved on day  15. FK506 and methotrexate
5mg/m2 on days 1, 3 and 6 was utilized for GVHD prophylaxis.
His course was complicated by moderate venoocclusive disease,
small subdural hemorrhage, and viremia. He has not had any
evidence of graft versus host disease. Initial chimerism (STRs)
showed approximately 63% donor derived cells, since increasing
with 100% T-cell engraftment. He clinically is doing well post
transplant. This case demonstrates that intrauterine transfusion
followed by unrelated donor UCBT is feasible for the treatment of
0thalassemia.
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CHRONIC GRAFT-VERSUS HOST DISEASE (GVHD) IN CHILDREN WITH
MUCOPOLYSACHARIDOSES (MPS) TWO YEARS AFTER UNRELATED DO-
NOR UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT)
Szabolcs, P.1, Martin, P.L.1, Parikh, S.1, Prasad, V.K.1, Vinesett, R.1,
Escolar, M.L.2, Kurtzberg, J.1 1Duke University Pediatric BMT Pro-
gram, Durham, NC; 2Center for Development and Learning, UNC-
CH, Chapel Hill, NC.
MPS are a group of metabolic storage diseases caused by lyso-
somal enzyme deﬁciencies resulting in the accumulation of glycos-
aminoglycans in multiple organs. Unrelated Cord Blood Trans-
plantion (UCBT) can prevent progression of organ dysfunction in
MPS. UCBT can slow or halt cognitive deterioration in early cases
of MPS II and III and improves cognitive outcome for MPS I.
However, even after full donor engraftment quality of life and
neurocognitive outcome can be adversely affected by post-trans-
plant complications such as chronic GVHD and its treatments. In
this retrospective analysis, we sought to determine how many
children receive systemic immunosuppressive (IS) drugs at the 2
year time point at the single largest center performing UCBT for
MPS. Over 90% of Duke patients with MPS are out of state and
are followed locally after 6-9 months. However, even these patients
return to Duke for yearly visits. Receiving systemic IS drugs was
chosen as a surrogate marker of active chrGvHD. Patients between
ages 1 and 50 months (median 18 months) underwent UCBT for
treatment of MPS I (Hurler), MPS II (Hunter), and MPSIII
(Sanﬁlippo Syndrome). Preparative regimen consisted of busul-
fan  cyclophosphamide with equine ATG as previously described
(COBLT study). Cyclosporine A and SoluMedrol were used as
GvHD prophylaxis. Systemic IS is expected to be tapered starting
between 6 and 12 months after UCBT. In the absence of active
GVHD, patients are weaned off all IS between 12-16 months
post-UCBT. Fourty seven (47) MPS patients were transplanted
between 1995 and September 2004, (MPSI n33, MPSII n2,
MPS IIIA n8 , MPS IIIB n4) Thirty three (33) out of the 47
were alive 2 years post-UCBT (70%). Ten out of the thirty three
survivors (30%) were receiving systemic IS drug at the 2 year visit
with the recommendation to continue. Five of these had limited
skin GvHD while ﬁve had skin plus other organ involvement
(cytopenias in 2 and GI tract in another 3). One received CellCept
only and two were on FK506 alone. Three children received 2
agents (FK506 and Prednisone). Four children received three drug
combination (FK506, low dose Prednisone, and Daclizumab).
Mean CD4 T cells were 1400/mm3  950. One patient died
before the 3 year f/up with compliactions related to GVHD, while
all other patients are alive. Taken together, a subset of MPS
patients experience prolonged exposure to IS drugs that may
hinder neurocognitive outcome after UCBT. Risk factors are cur-
rently analyzed.
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KINETICS OF ENGRAFTMENT FOLLOWING DUAL UNRELATED CORD
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Reduced intensity conditioning (RIC) is a safer alternative to
conventional myeloablative conditioning for patients at high risk of
transplant-related morbidity/ mortality. For these patients lacking
adult donors, unrelated donor cord blood transplant (CBT) is a
feasible alternative. However, CBT with RIC may pose unaccept-
able risks of graft rejection, hence compromising outcome. To
enhance engraftment, dual donors CBTs with RIC have been
performed with promising results in pediatric patients in our cen-
tre. Little is known on the kinetics of engraftment and the deﬁning
factor/s determining the ﬁnal engrafted unit in this setting. We
analyzed these variables in 8 patients (6 with acute lymphoblastic
leukemia (ALL), 1 with hemophagolymphohistiocytosis (HLH), 1
with CD40 ligand deﬁciency) who received mismatched, dual un-
related CBT after RIC with ﬂudarabine, cyclophosphamide, low
dose TBI  low dose ATG between 2004 - 2006. All except the
patient with HLH engrafted. In 6 evaluable patients, mixed chi-
merism was noted in 50% of the patients early after transplant
(D14). Analyzed separately, all patients with ALL achieved 
90% donor chimera by D34 after transplant. All but 1 patient
with ALL (83%) are in continuous complete remission to date.
The patient with CD 40 ligand achieved complete donor chimera
on D125 after transplant. Contrary to reports of prolong mixed
chimera states after RIC, which may predispose to graft failure and
relapse, the kinetics of engraftment in our patients with ALL was
quick and robust. Early engraftment kinetics also revealed domi-
nance of one of the two units in majority of these patients.
Amongst other factors, the ﬁnal engrafted cord units have higher
post-thaw cell doses. These data demonstrated that sustained, full
donor chimera can be achieved early after RIC transplants with
dual CBT in pediatric patients with ALL without compromising
survival and relapse risks.
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College of Medicine and Public Health, Columbus, OH; 2Department of
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Autologous stem cell transplant has failed to demonstrate beneﬁt
in most children with relapsed acute myelogenous leukemia. Ten
to twenty percent of children with acute promyelocytic leukemia
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(APL) treated using all-trans-retinoic acid (ATRA) based therapy
will relapse. An analysis of salvage therapy in patients  66 years
old from two sequential European multi-center trials demonstrated
the efﬁcacy of autologous peripheral blood stem cell transplant
(PBSCT) performed during molecular remission.
Since 2004, APL recurred in four patients following ATRA based
therapy. Table 1 (below) summarizes their clinical characteristics.
After achieving molecular remission, the patients received cyclo-
phosphamide 2 gm/m2 for two days followed by G-CSF mobili-
zation. All PBSC products were negative for PML-RARA by RT-
PCR. To date, three patients received stem cell infusions following
cyclophosphamide (60 mg/kg X 2 days) and total body irradiation
(200 cGy X 6).
All three transplanted patients remain in molecular remission 27,
13, and 8 months following PBSCT. Engraftment of WBC oc-
curred at 13, 15 and 18 days, with discharge days of 16, 18, and 20
post-PBSCT. Maximum toxicity was Grade III mucositis (NCI
CTC v.3.0).
PML-RARA negative stem cells can be mobilized in pediatric
patients after arsenic trioxide or FLAG therapy using cyclophos-
phamide and G-CSF. Three patients have durable molecular re-
mission following PBSCT. Autologous PBSCT is an option for
pediatric patients with relapsed APL that avoids the complications
of graft vs host disease, prolonged immunosuppression, and the
higher transplant related mortality of allogeneic transplantation.
Table 1. Clinical characteristcs, salvage therapies and mobilization
outcome.
Age at dx
(yrs)/gender
Sanz Risk
Group1
Length
CR 1
(mos)
Relapse
Site
Re-induction
therapy
# days
harvested
Total
CD34/kg
X 106
14 M High 11 Marrow
 CNS
Arsenic trioxide
 Intrathecal
Ara-C
3 2.19
15 M Intermediate 24 Marrow Arsenic trioxide 3 2.35
2 M Intermediate 14 CNS FLAG2 
Intrathecal Ara-
C and
Methotrexate
1 207.00
12 M Low 26 Marrow Arsenic
Trioxide
1 14.53
1 Sanz, Blood 2000: 96(4), 1247-1253 2 FLAG (ﬂudarabine 25
mg/m2 X 5 days; cytarabine 2 gm/m2 X 5 days; G-CSF)
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HIGH-DOSE THIOTEPA, BUSULFAN, AND CYCLOPHOSPHAMIDE FOR
ALLOGENEIC STEM CELL TRANSPLANTION IN RISK PEDAITRIC PA-
TIENTS WITH HIGH-RISK LEUKEMIAS
Worth, L.L.1, Koontz, S.E.1, Petropoulos, D.1, Tran, H.T.1,
Choroszy, M.S.1, Chan, K.2 1University of Texas M D Anderson Cancer
Center, Houston, TX; 2Texas Transplant Institute, San Antonio, TX.
Between 1992 and 2003, 50 children at M D Anderson Cancer
Center with high-risk leukemias received thiotepa (250 mg/m2 x 3),
busulfan (1 mg/kg q 6 hrs x 12 orally or 0.8 mg/kg q 6 hrs iv x 12),
and cyclophosphamide (60mg/kg x 2) as a preparative regimen for
allogeneic stem cells transplantation. High-risk ALL patients (25)
had abnormal cytogenetics (Ph, 11q23), CR2 after early relapse,
 CR3, or were induction failures. Patients will AML (25) were
included if they had CR 2, MDS, or were induction failures.
Sixteen patients were transplanted with active disease ( 5% blasts
on bone marrow aspirate). Busulfan was given orally until 1999
when the intravenous preparation was available. Stem cell sources
included HLA matched family members (21) and unrelated mar-
row and cord blood (29). Two patients failed to engraft and went
on to receive a second transplant. Neutrophil engraftment (ANC
500) occurred at a median of 17.5 days (range 11-63) and platelet
counts50,000/L at a median of 44.5 days (range 13-394). Grade
3-4 toxicities occurred in 24 patients and were predominantly
esophagitis and mucositis, emesis, and hepatic dysfunction. All
three patients who developed VOD had received busulfan orally.
One patient did not have pharmacokinetics performed secondary
to machine malfunction. One patient had an acceptable AUC. The
ﬁnal patient had an elevated BU dose that was decreased based on
initial pharmacokinetics. Grades I -II acute GVHD was common
(27 patients). Grades III-IV occurred in 5 patients. Five patients
developed limited chronic GVHD, and 9 patients developed ex-
tensive chronic GVHD. Nineteen patients are alive and well a
median of 7.0 years (range 3.0 - 13.9). Thirty-one patients died of
recurrent disease (13), infection (6), GVHD (5), VOD (3), other
causes (4). The two patients who failed to engraft and underwent a
second transplant died of disease recurrence. Children with high-
risk leukemias are difﬁcult to cure even with high-dose chemother-
apy and stem cell transplantation. Of the 16 patients transplanted
with active disease, only the patients with AML are long term
survivors, suggesting that this regimen alone will not result in a
cure, but that additional strategies are required for children with
active ALL. This chemotherapeutic regimen had some signiﬁcant
toxicities, however, after the development of intravenous busulfan,
this regimen had a signiﬁcant decrease in nausea and there were no
incidence of VOD suggesting further evaluation.
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A NOVEL RAG-1 NULL MUTANT DISPLAYS SEGREGATION OF DNA
CLEAVAGE INTO TRANSPOSITION ACTIVITY IN THREE CHILDREN WITH
T-B-NKSCID
Xiao, T.Z.1, Dunn, E.A.1, Yannone, S.M.2, Cowan, M.J.1 1Pediatric
Bone Marrow Transplant Division, UCSF Children’s Hospital, 505
Parnassus Ave, San Francisco, CA; 2Life Sciences Division, Department
of Molecular Biology, Lawrence Berkeley National Laboratory, 1 Cyclo-
tron Road, Berkeley, CA.
RAG (recombination activating gene)-1 and RAG-2 initiate
V(D)J recombination by cleaving DNA at recombination signal
sequences (RSS) through sequential nicking and transesteriﬁcation
reactions to yield blunt signal and coding ends terminating in DNA
hairpin structures. Ubiquitous DNA double strand repair factors in
the non-homologous ending joining (NHEJ) pathway then medi-
ate the rejoining of broken DNA. Severe combined immunodeﬁ-
ciency disease (SCID) comprises a heterogeneous group of primary
immunodeﬁciencies, a proportion of which are due to mutations in
RAG-1, RAG-2 or in NHEJ factors, respectively. Here, we report
a novel RAG-1 null mutation, R776W, identiﬁed in three familial
related children from the Dine´ Native American tribe who mani-
fest a classic T-B-NKSCID phenotype and engraftment of ma-
ternal T cells. Unlike Artemis mutations among Athabascan-speak-
ing Native Americans, which trigger accumulation of the hairpin
structure, this RAG-1 null mutant evokes impaired DNA cleavage
and binding activity in vitro by preferentially diminishing hairpin
formation. Moreover, the V(D)J recombination efﬁciency of this
mutant is also reduced as assessed by an enhanced green ﬂuores-
cent protein (EGFP) based V(D)J recombination assay. However,
the catalysis of other DNA strand transfer reaction, such as trans-
position, is not substantially affected by this RAG-1 mutant. These
results indicate that dysfunction of RAG-1 is responsible for the
T-B-NKSCID phenotype. Segregation of RAG-1 mediated DNA
cleavage activity into its transposition activity casts a new light on
RAG-1’s roles in V(D)J recombination and translocation.
SOLID TUMORS
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FEASIBILITY OF AUTOLOGOUS STEM CELL TRANSPLANT FOLLOWED
BY REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION
FOR HIGH RISK NEUROBLASTOMA: A SINGLE INSTITUTION PILOT
STUDY
Yamashiro, D.J.1, Lee, A.1, Bhatia, M.1, Glade-Bender, J.1,
Qualter, E.1, Militano, O.1, Harrison, L.A.1, Davenport, V.1,
Cheung, K.1, Bradley, M.B.1, Garvin, J.H.1, Del Toro, G.1,
Cairo, M.S.1 1Columbia University, New York, NY.
Background: Autologous stem cell transplant (AutoSCT) has
improved the outcome for children with high risk (HR) neuroblas-
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